Evidence map›Paper›PMID 40795179›Full record

ArticleCardiovascular research2025

YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.

Wenchu Ye, Wentao Gao, Cheng Kiu Ho, Lei Cui, James Y W Lau, Xiao Yu Tian, Bin Zhou, Kathy O Lui

Abstract read
In one paragraph

Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Wenchu YeCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, Department of Chemical Pathology, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Room 306D, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Hong Kong, China.
Wentao GaoCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, Department of Chemical Pathology, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Room 306D, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Hong Kong, China.
Cheng Kiu HoCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, Department of Chemical Pathology, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Room 306D, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Hong Kong, China.
Lei CuiCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, Department of Chemical Pathology, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Room 306D, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Hong Kong, China.
James Y W LauDepartment of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Xiao Yu TianSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-3472-9898
Bin ZhouCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, New Cornerstone Investigator Institute, State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Kathy O LuiCAS CEMCS-CUHK Joint Laboratory for Cardiovascular Sciences, Department of Chemical Pathology, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Room 306D, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Hong Kong, China.ORCID 0000-0002-1616-3643

Funding

Chinese Academy of Sciences-Croucher Funding Schemes for Joint LaboratoriesCroucher Foundation Innovation AwardInnovation and Technology Fund ITS/252/21National Natural Science Foundation of China 81922077National Natural Science Foundation of China 82000407National Natural Science Foundation of China 82070494Research Grants Council of Hong Kong 14100021Research Grants Council of Hong Kong 14108420Research Grants Council of Hong Kong C4004-23YResearch Grants Council of Hong Kong C7004-22YResearch Grants Council of Hong Kong M-402-20Research Grants Council of Hong Kong RFS2223-4S04Research Grants Council of Hong Kong T12-101/23-NResearch Grants Council of Hong Kong Joint Research Scheme N_CUHK4104/24University Grants Committee Research Matching Grant Scheme
6 · The paper itself

Abstract

aimsRecent genome-wide association study analysis has identified YY1 as a novel locus associated with blood pressure traits; however, whether YY1 directly controls vasoreactivity remains unknown. The principal function of vascular smooth muscle cells (VSMCs) is to contract, which is essential for regulating vascular tone, blood flow, and blood pressure. We hypothesized that YY1, a transcription factor, facilitates vascular function by epigenetically regulating gene expression in VSMCs. METHODS AND

resultsThe effects of VSMC-specific YY1 loss were studied in mice. Lineage tracing, calcium imaging, and wire myography were performed to assess vasoreactivity. Genome-wide analysis through RNA-seq, ChIP-seq, m6A-seq, RNA immunoprecipitation, and transcript stability assays were conducted to evaluate gene expression and regulation. Co-immunoprecipitation was performed to study interactions between YY1 and chromatin regulators. AAV-mediated SM22-specific gene delivery was used to rescue vascular function in vivo. Contractile VSMCs were differentiated from human embryonic stem cells for in vitro experiments. Hypertension was induced in vivo using salt and L-NAME treatments. We demonstrate that vascular contraction and blood pressure are significantly reduced in Myh11CreER;Yy1fl/fl mice. YY1 does not regulate VSMC proliferation, survival, calcium entry, or membrane polarization in homeostasis. Integrative analyses of transcriptomics, epitranscriptomics, and epigenetics identified Mettl3 as a putative downstream target of YY1. Like YY1 loss-of-function, impaired vascular contraction and reduced blood pressure were observed in Myh11CreER;Mettl3fl/fl mice. Mylk2, Tgfb2, and Myh11 were significantly down-regulated after genetic ablation of Yy1 or Mettl3 in VSMCs. Further analysis showed that Mettl3-mediated m6A mRNA methylation stabilizes the transcripts of these genes, possibly through the m6A reader IGF2BP1. AAV-mediated, VSMC-specific Mettl3 gene delivery significantly improved vascular contractility in Yy1-deficient mice, functionally confirming Mettl3 as a direct downstream target of YY1. Mechanistically, YY1 binds to the Mettl3 promoter near regions of H3K4 trimethylation and activates Mettl3 transcription by recruiting Set1A-Wdr82 complex for H3K4me3 deposition. Both Myh11CreER;Yy1fl/fl and Myh11CreER;Mettl3fl/fl mice exhibited delayed onset of hypertension.

conclusionYY1 maintains vascular contraction and regulates blood pressure by stabilizing Mylk2, Tgfb2, and Myh11 transcripts through the activation of Mettl3 transcription in VSMCs. These findings provide novel insights into the epigenetic control of VSMC epitranscriptomes and unravel a new mechanism underlying VSMC-mediated vasoconstriction through the YY1/Mettl3 regulatory axis. Additionally, our results demonstrate a clinically relevant role for the YY1/Mettl3 axis in mitigating hypertension and regulating blood pressure under both normal and hypertensive conditions.

Indexed as

Blood PressureEpigenesis, GeneticHypertensionMuscle, Smooth, VascularMyocytes, Smooth MuscleRNA, MessengerRNA Processing, Post-TranscriptionalVasoconstrictionYY1 Transcription FactorAdenosineAnimalsCells, CulturedDisease Models, AnimalHumansMaleMethyltransferasesAdenosineMethyltransferasesMettl3 protein, mousemyosin 11, mouseMyosin Heavy ChainsN-methyladenosineRNA, MessengerYy1 protein, mouseYY1 Transcription FactorBlood pressureHypertensionm6AMettl3Smooth muscle contractionVascular resistanceYY1

Identifiers

PMID40795179
PMCPMC12551392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.